Kohlberg Kravis Roberts

Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.

Taski Ahmed

Principal, KKR Prisma

Mustapha Angwa

CEO

Anne Arlinghaus

Managing Director

Joe Bae

Co-President and Co-COO

David Biener

VP Finance

Todd Builione

Member, President of KKR Credit

Jim Burns

Partner

Daniel Celeghin

Managing Director, Client and Partner Group

Spencer Chavez

Principal

Mukul Chawla

Partner, Head of Asia Pacific Growth Equity

Steve Codispoti

Director, Finance

Benjamin Conner

Managing Director

Kendra Decious

Director, Finance

Patrick Devine

Director

Brian Dillard

Partner and Head of Asia Credit

Brandon Donnenfeld

Director

Jamison Ely

Director

Mark Ennis

Director

Len Fliegel

Director

Marco Fontana

Managing Director

Brandon Freiman

Partner, Head of North American Infrastructure

Philipp Freise

Co-Head of European Private Equity

Terence Gallagher

Managing Director

Travers Garvin

Director, Public Affairs

Felix Gernburd

Managing Director

Alan Grant

Principal, KKR Capstone

Elizabeth Hammond

Managing Director

Chris Harrington

Partner

Erich Heintzen

Director

Jill Henn

Managing Director, Human Capital

Sota Horiuchi

Principal, Private Equity

Jeff Van Horn

Managing Director, Credit

Paul Horwood

CFO, European Operations

Mark Hunt

Director, Capital Management Group

Johannes P. Huth

Managing Director and Head of KKR EMEA

Hisao Iijima

Principal, Private Equity

Gary H. Jacobs

Managing Director, Capital Management Group

Zhen Ji

Managing Director, China

Franziska Kayser

Managing Director

Kazuyuki Kido

Managing Director

Philip Kim

Managing Director

Thomas Kim

Managing Director and Global Risk Manager

Daan Knottenbelt

Partner

Rie Koike

Principal, Client and Partner Group

Joan Lacagnina

Managing Director, Finance

Jeremiah Lane

Principal

Dashiell Lane

Director, Energy and Infrastructure

David Lang

Partner

Joshua Lederman

Principal and Associate

Elissa Leechawengwongs

Principal, Private Equity

Vincent Letteri

Managing Director, TMT Growth Equity

Robert Lewin

Partner

Xiang Li

Managing Director, Private Equity

Frances Lim

Managing Director, Global Macro and Asset Allocation and Portfolio Mgt of Strategic Partnerships

Max Lin

Partner and Director, Private Equity

Lucy Liu

Director, Client and Partner Group

Ming Lu

Partner and Co-Head of Asia Private Equity Business

Rony Ma

Director

Blaine MacDougald

Director and Co-head of Credit Research, Credit

Emily Mason

Principal, KKR Prisma

Kyle Matter

Director

Patrick Mattson

Managing Director

Kevin McMahon

Managing Director

Hilary McNamara

Director, Business Operations

David McNellis

Managing Director, Global Macro and Asset Allocation

Henry McVey

Partner and Head of Global Macro and Asset Allocation, CIO of KKR Balance Sheet

Ken Mehlman

Partner and Global Head of Public Affairs; Co-head KKR Global Impact

Jimmy Miele

Principal

George Mueller

Managing Director

Katherine T. B. de Mul

Director, Operations and Client Services

Narender Nanchary

Principal, Hedge Funds

Sanjay Nayar

CEO

William Needham

Managing Director

Sean Nelson

Director

Lesley Nurse

Director, Client and Partner Group

Scott Nuttall

Co-CEO

Ted Oberwager

Principal, Private Equity

Christian Ollig

Director, Private Equity

Timotheus Osnabrug

Director, Private Equity

John Park

Director, Private Equity

Chung Ho Park

Director, Private Equity

Vishal Patel

Managing Director

Clayton Perry

Managing Director, Client and Partner Group

Daniel Pietrzak

Partner

Samuel Plotner

Director

Jaka Prasetya

Partner

Sharath Reddy

Director, Credit

John Reed

Director, Credit

Janice Cook Roberts

Director, Client and Partner Group

Paul Roberts

Managing Director, KKR Prisma

James Rudy

Director, Principal Activities

Jean -Pierre Saad

Director, Private Equity

Matt Salem

Partner and Head of RE Credit

Kaveh Samie

Managing Director, Client and Partner Group

Richard Sarnoff

Managing Director

Kugan Sathiyanandarajah

Managing Director and Head of Healthcare Strategic Growth in Europe

Jeffrey Schachter

Managing Director

Lucian Schönefelder

Partner

Vance Serchuk

Managing Director, Americas Private Equity, Industrials Team

Stephen Shanley

Partner

Peggy Shaughnessy

Managing Director, Business Operations

Blake Shorthouse

Managing Director

Rob Siegel

Director, Information Technology

Tashwinder Singh

Director, Capital Markets

Duncan Smith

Principal, Credit

Pete Stavros

Co-Head of Global Private Equity

Chris Sun

Partner, Private Equity

Karan Swani

Director, Private Equity

Marta Szczerba

Director

Waldemar Szlezak

Managing Director

Weiyu Tan

Managing Director

Nate Taylor

Co-Head of Americas Private Equity

Paige Thacher

Principal

Cade Thompson

Partner, Capital Markets

Gaurav Trehan

Head of Asia Private Equity

Cecilio Velasco

Managing Director

Steven Wang

Principal, Private Equity

Douglas Watt

Managing Director

Joshua T. Weisenbeck

Partner

Dave Welsh

Partner and Head of Technology Growth Equity

Ryan L.G. Wilson

Managing Director

Alisa A. Wood

Partner

Angela Yang

Principal, Credit

Annie Yangeksakul

Principal, Hedge Funds

Eiji Yatagawa

Partner

Past deals in Health Diagnostics

HealthCare Global Enterprises

Acquisition in 2025
HealthCare Global Enterprises is a cancer center is a center which offers complete diagnosis and treatment radiation, surgical and medical oncology services under one a single roof. cancer care services. The also operate fertility clinics, multi-specialty hospitals providing cardiology, neurology, orthopedics, gastroenterology, urology, pulmonary and critical care services. Its service offerings comprise of the clinical lab, diagnosis, robotic surgery, bone marrow transplantation, and radiation oncology.

HealthCare Global

Acquisition in 2025
HealthCare Global they focuses on cancer care, tertiary care, infertility treatment, advanced screening, and diagnostics.

Henry Schein

Post in 2025
Henry Schein is a leading provider of healthcare products and services, primarily catering to office-based dental, medical, and animal health practitioners. The company operates through two main segments: healthcare distribution and technology & value-added services. In its healthcare distribution segment, Henry Schein combines global dental and medical businesses to distribute a wide range of consumable products, small equipment, laboratory supplies, and vitamins. The technology and value-added services segment focuses on offering practice management software and other technological solutions that enhance operational efficiency for healthcare professionals. With a strong emphasis on leveraging a network of people and technology, Henry Schein aims to support practitioners in delivering high-quality care.

Immedica

Acquisition in 2024
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East. Immedica provides significant know-how and experience from the commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access to specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution. Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.

Cortex

Private Equity Round in 2023
Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.

Clinisupplies

Acquisition in 2022
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.

Digital Diagnostics

Series B in 2022
Digital Diagnostics Inc. is an artificial intelligence diagnostics company focused on enhancing the quality, accessibility, and affordability of healthcare through advanced technology. Founded in 2010 in Coralville, Iowa, by Michael Abramoff, the company has developed a range of autonomous algorithms that analyze medical images to detect various diseases. Its flagship products include IDx-DR for diabetic retinopathy, IDx-G for glaucoma indicators, and IDx-AMD for age-related macular degeneration. Additionally, Digital Diagnostics provides algorithms for detecting other conditions such as Alzheimer's disease and cardiovascular risks. By eliminating the diagnostic burden from specialists, the company's AI platform aims to establish a new standard of care, democratizing healthcare and improving patient outcomes. The company collaborates with patient advocacy groups and regulatory bodies to facilitate the adoption of its innovative solutions both in the United States and internationally.

Clarify Health Solutions

Series D in 2022
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.

Brightline

Series C in 2022
Brightline, Inc. is a provider of pediatric behavioral health care services, established in 2019 and headquartered in Palo Alto, California. The company offers a range of services including behavior therapy, psychiatry and medication support, speech-language therapy, and occupational therapy. Brightline operates as a technology-enabled behavioral health home, utilizing innovative technology and virtual services to deliver integrated care. Its collaborative care team focuses on supporting children throughout their developmental stages and addressing the needs of their families. Brightline was previously known as Emilio Health, Inc. and rebranded in May 2020.

Biosynth

Acquisition in 2021
Biosynth is a custom synthesis and manufacturing services company that aims to streamline the fragmented supply chain in the pharmaceutical and diagnostics sectors. By enhancing the availability of complex chemicals, peptides, and biological materials, Biosynth increases the productivity of its clients, facilitating faster development and market introduction of new therapies and diagnostic assays. The company offers a comprehensive range of products, including carbohydrates, nucleosides, enzyme substrates, and natural products, as well as a research product catalog featuring over one million items to support research and development efforts. With global research, manufacturing, and distribution facilities, Biosynth caters to the needs of diagnostic and pharmaceutical companies, ensuring they have access to essential materials for their product development.

Sapphiros

Series A in 2021
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

Paige

Series C in 2021
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

Clinisupplies

Acquisition in 2020
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.

ELSAN

Acquisition in 2020
ELSAN provides medical services. The Company offers cancer treatment, obstetrics, pediatrics, and cardiology, as well as diagnosis, follow up care, and surgical services. Vedici serves patients and medical professionals throughout France.

Univercells

Venture Round in 2020
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

BrightSpring Health Services

Acquisition in 2019
BrightSpring Health Services is a comprehensive healthcare platform that offers a range of clinical, nonclinical, pharmacy, and ancillary care services tailored for individuals across various ages and health conditions. As one of the largest providers of home and community-based health services, BrightSpring specializes in serving complex and high-cost populations. Its primary offerings include behavioral health services, such as autism support, home health care encompassing personal care, hospice, and neuro therapy, as well as job placement and vocational training. The company also utilizes pharmacy solutions and telecare technologies to enhance its service delivery, focusing on patients covered by Medicare, Medicaid, and commercial insurance. The majority of its revenue is derived from its Pharmacy Solutions segment, underscoring its commitment to integrated care for diverse patient needs.

Hetian Group

Acquisition in 2018
HeTian is a professional hospital management company specialized in operating and investing in integrated health care service providers. HeTian currently operates seven award-winning hospitals and health care centers focused on underserved Chinese cities. The company’s vision is to improve access to quality health care services by building a network of primary medical care providers supported by modern health care management best practices.

Clarify Health Solutions

Series B in 2018
Clarify Health Solutions, Inc. operates a data-driven platform designed to enhance patient care by facilitating real-time engagement among patients, clinicians, and care teams. The platform, known as Clarify Episode, utilizes real-time data to optimize care workflows, stratify patients based on various characteristics, and identify potential complications early on. Key components of the platform include Care Pilot, which empowers patients in their healthcare journey; Care Connect, which allows clinicians to monitor and intervene as needed; and Care Prism, which provides management with essential business analytics. By leveraging machine learning and data analytics, Clarify Health offers solutions that improve transparency, personalization, and engagement for patients while streamlining tasks for healthcare professionals. The company, founded in 2015 and based in San Francisco, has formed a strategic alliance with Leidos to further enhance its offerings.

Envision Healthcare

Acquisition in 2018
Envision Healthcare is a provider of physician-led, outsourced medical services that offers a comprehensive range of healthcare solutions. The company serves consumers, hospitals, healthcare systems, health plans, and government entities at various levels. Its services span the continuum of care, including medical transportation, ambulatory surgery, home health services, clinical solutions, and post-acute patient care. By focusing on coordinated, clinically-based care, Envision Healthcare aims to enhance the patient experience while also working to reduce overall healthcare costs.

Angelica Corp

Acquisition in 2017
Angelica Corporation is the provider of textile rental and linen management services to the U.S. healthcare market. The organization provides laundry and linen management services to hospitals, long term care facilities, and out-patient medical practices from 26 service centers across the nation.

Apollo Hospitals

Post in 2013
Apollo Hospitals is widely recognized as the pioneer of private healthcare in India, and was the country’s first corporate hospital. The Apollo Hospitals Group, which started as a 150-bed hospital and today, operates 9200 beds across 64 hospitals. A forerunner in integrated healthcare, Apollo has a robust presence across the healthcare spectrum. The Group has emerged as the foremost integrated healthcare provider in Asia, with mature group companies that specialize in insurance, pharmacy, consultancy, clinics and many such key touch points of the ecosystem. The Apollo Group has touched the lives of over 45 million patients, from 121 countries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.